Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

dustin1101 Sep. 18 at 5:26 PM

$AXGN I'll be bidding for some right around $44, perhaps just below, and somewhere between 42.50-43. I don't think it goes below offering price unless the market suddenly unravels. Consolidate this quick rebound and then back for the 46-47 battle again IMO.

1 · Reply

dustin1101 Sep. 17 at 3:10 PM

$AXGN took off what I added below. Seems to be running out of steam just a bit and a pullback to retest a support level wouldn't be surprising. Depends what the buyers of late still have to do, they've been having fun squeezing shorts since 40. Still MT LT bullish.

1 · Reply

dustin1101 Sep. 16 at 2:27 PM

$AXGN There's some big money pushing around here, mostly coming IN. Watch the tape. Very impressive demand for shares. FOMC today, there'll be some volatility to play. GL

1 · Reply

dustin1101 Sep. 15 at 7:54 PM

$AXGN shorts from the last drop are losing one battle after another in this rise.

0 · Reply

dustin1101 Sep. 15 at 5:30 PM

$AXGN Jefferies' Michael Sarcone reiterated a $55 target today. Analysts so far either maintaining or raising targets in reaction to the BioCircuit purchase.

0 · Reply

dustin1101 Sep. 15 at 3:06 PM

$AXGN Clear accumulation despite the market.

0 · Reply

dustin1101 Sep. 14 at 6:33 PM

$AXGN Lake Street 50 > 55 today.

0 · Reply

dustin1101 Sep. 14 at 3:50 PM

$AXGN up 4 bucks off the lows Friday. Good start!

0 · Reply

dustin1101 Sep. 11 at 3:36 PM

$AXGN when it get's into this mode it always feels like the selling will never end (that's their goal) and then suddenly it does, and it climbs back through the dollars lost. I just don't see how this acquisition makes a bear case. Perhaps it was expensive, but the valuation on a company at that stage, that aligns with your company's strategy is pretty subjective. GLTA. Time to get outside and enjoy some fantastic New England weather.

0 · Reply

Battlesign Sep. 11 at 2:34 PM

$AXGN ~10.3× sales, ~74× forward earnings and >300× trailing FCF, while still reporting a GAAP loss. Shares outstanding had risen 9.3% YoY before yesterday’s offer. Yesterday’s offer will add another 9%-10.5%

0 · Reply

Axogen Transcript: M&A announcement

Sep 10, 2026, 8:00 AM EDT - 10 days ago

Axogen Press release: M&A announcement

Sep 10, 2026, 8:00 AM EDT - 10 days ago

Axogen Slides: M&A announcement

2026-09-10T10:21:09.000Z - 10 days ago

AxoGen 4.91M share Secondary priced at $42.50

2026-09-10T10:05:25.000Z - 10 days ago

AxoGen to acquire BioCircuit Technologies

Sep 10, 2026, 6:01 AM EDT - 10 days ago

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Sep 10, 2026, 6:00 AM EDT - 10 days ago

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Sep 1, 2026, 7:00 AM EDT - 19 days ago

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

2026-08-26T09:25:09.000Z - 25 days ago

AxoGen initiated with a Buy at Truist

2026-07-30T13:32:21.000Z - 7 weeks ago

AxoGen price target raised to $55 from $50 at Jefferies

2026-07-30T11:06:55.000Z - 7 weeks ago

AxoGen price target raised to $55 from $50 at Canaccord

2026-07-30T10:05:29.000Z - 7 weeks ago

AxoGen price target raised to $53 from $50 at H.C. Wainwright

2026-07-30T09:45:16.000Z - 7 weeks ago

AxoGen price target raised to $55 from $50 at Citizens

2026-07-29T18:35:42.000Z - 7 weeks ago

AxoGen price target raised to $55 from $50 at Jefferies

Jul 29, 2026, 8:00 AM EDT - 7 weeks ago

Axogen Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 7 weeks ago

Axogen Slides: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 7 weeks ago

Axogen Quarterly report: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 7 weeks ago

Axogen Earnings release: Q2 2026

2026-07-29T11:30:31.000Z - 7 weeks ago

AxoGen reports Q2 adjusted EPS 12c, consensus 12c

2026-07-29T11:30:18.000Z - 7 weeks ago

AxoGen raises FY26 revenue view to $279M from $270M, consensus $270.92M

2026-07-29T11:20:58.000Z - 7 weeks ago

Trace Biosciences announces strategic investment from Axogen

Jul 29, 2026, 7:05 AM EDT - 7 weeks ago

Axogen, Inc. Reports Second Quarter 2026 Financial Results

Jul 28, 2026, 9:00 AM EDT - 7 weeks ago

Axogen Slides: Corporate presentation

2026-07-20T20:15:49.000Z - 2 months ago

Neuronetics appoints Nir Naor as CFO, CLO Andrew Macan to step down

STIM

Jul 15, 2026, 7:00 AM EDT - 2 months ago

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Axogen Transcript: AGM 2026

May 13, 2026, 12:35 PM EDT - 4 months ago

Axogen Transcript: Bank of America Global Healthcare Conference 2026

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

2026-04-29T16:57:39.000Z - 4 months ago

AxoGen price target raised to $48 from $41 at Raymond James

2026-04-29T13:02:40.000Z - 4 months ago

AxoGen price target raised to $50 from $45 at Canaccord

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Axogen Proxy statement: Proxy filing

2026-04-29T10:16:26.000Z - 4 months ago

AxoGen price target raised to $50 from $39 at H.C. Wainwright

2026-04-29T09:53:29.000Z - 4 months ago

AxoGen price target raised to $50 from $42 at Citizens

2026-04-28T14:28:46.000Z - 4 months ago

AxoGen rises 12.8%

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Slides: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Axogen Quarterly report: Q1 2026

2026-04-28T11:49:44.000Z - 4 months ago

AxoGen raises FY26 revenue view to $270M from $265.7M, consensus $265.89M

2026-04-28T11:08:24.000Z - 4 months ago

AxoGen reports Q1 adjusted EPS 7c, consensus 7c

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Axogen, Inc. Reports First Quarter 2026 Financial Results

2026-04-24T11:16:41.000Z - 4 months ago

AxoGen price target raised to $45 from $40 at Canaccord

Apr 14, 2026, 7:00 AM EDT - 5 months ago

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

Mar 10, 2026, 12:30 PM EDT - 6 months ago

Axogen Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:00 PM EDT - 6 months ago

Axogen Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 6:00 AM EST - 6 months ago

Axogen Slides: Corporate presentation

Mar 3, 2026, 3:25 PM EST - 6 months ago

Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Axogen Slides: Q4 2025

Feb 17, 2026, 7:00 AM EST - 7 months ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 7 months ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 21, 2026, 11:18 PM EST - 8 months ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 8 months ago

Axogen Announces Proposed Public Offering of Common Stock

Jan 15, 2026, 1:30 PM EST - 8 months ago

Axogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 1:30 PM EST - 8 months ago

Axogen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 9 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 9 months ago

FDA approves Axogen's nerve repair graft

Dec 2, 2025, 12:30 PM EST - 9 months ago

Axogen Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 11:30 AM EST - 10 months ago

Axogen Transcript: Jefferies London Healthcare Conference 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Earnings release: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Axogen Slides: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 11 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Aug 25, 2025, 6:40 AM EDT - 1 year ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Axogen Slides: Q2 2025

Jul 29, 2025, 4:10 PM EDT - 1 year ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 1 year ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Axogen Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings release: Q1 2025

May 8, 2025, 7:05 AM EDT - 1 year ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Axogen Proxy statement: Proxy Filing

Apr 24, 2025, 8:04 AM EDT - 1 year ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Axogen Transcript: Investor Day 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Axogen Slides: FY 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Slides: Q4 2024

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Slides: Q3 2024

Sep 6, 2024, 7:00 AM EDT - 2 years ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Axogen Slides: Q2 2024

Aug 8, 2024, 7:05 AM EDT - 2 years ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 2 years ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 29, 2024, 4:40 PM EDT - 2 years ago

Axogen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 28, 2024, 4:30 PM EDT - 2 years ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings Call Transcript: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Quarterly report: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings release: Q1 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 2 years ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Axogen Proxy statement: Proxy Filing

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Axogen Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Axogen Registration statement: Registration Filing

Mar 6, 2024, 7:00 AM EST - 2 years ago

Axogen Registration statement: Registration Filing

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Earnings Call Transcript: Q4 2023

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Annual report: Q4 2023

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 30, 2023, 8:50 AM EST - 2 years ago

Axogen Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 8:00 AM EST - 2 years ago

Axogen Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

Axogen Quarterly report: Q3 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

Axogen Earnings release: Q3 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

Axogen Slides: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

dustin1101 Sep. 18 at 5:26 PM

1 · Reply

dustin1101 Sep. 17 at 3:10 PM

1 · Reply

dustin1101 Sep. 16 at 2:27 PM

$AXGN There's some big money pushing around here, mostly coming IN. Watch the tape. Very impressive demand for shares. FOMC today, there'll be some volatility to play. GL

1 · Reply

dustin1101 Sep. 15 at 7:54 PM

$AXGN shorts from the last drop are losing one battle after another in this rise.

0 · Reply

dustin1101 Sep. 15 at 5:30 PM

$AXGN Jefferies' Michael Sarcone reiterated a $55 target today. Analysts so far either maintaining or raising targets in reaction to the BioCircuit purchase.

0 · Reply

dustin1101 Sep. 15 at 3:06 PM

$AXGN Clear accumulation despite the market.

0 · Reply

dustin1101 Sep. 14 at 6:33 PM

$AXGN Lake Street 50 > 55 today.

0 · Reply

dustin1101 Sep. 14 at 3:50 PM

$AXGN up 4 bucks off the lows Friday. Good start!

0 · Reply

dustin1101 Sep. 11 at 3:36 PM

0 · Reply

Battlesign Sep. 11 at 2:34 PM

0 · Reply

dustin1101 Sep. 11 at 2:28 PM

$AXGN The tree is shaking. Sky must be falling.

0 · Reply

dustin1101 Sep. 11 at 1:06 PM

$AXGN Wells Fargo and Cannacord today reiterate the same price targets as before. $48 and $55.

0 · Reply

dustin1101 Sep. 10 at 6:17 PM

Times I've regretted adding shares of $AXGN on a dip: Nil

0 · Reply

quassarcapital Sep. 10 at 5:14 PM

$AXGN falls about 5% premarket after Axogen agreed to acquire BioCircuit Technologies for $200M in cash, funding the deal through a newly priced $208.7M stock offering at $42.50 per share.

0 · Reply

Tekoa Sep. 10 at 3:50 PM

Why analysts like the deal announced by $AXGN today: 1) Adds NerveTape™, the first FDA‑approved sutureless nerve repair device, broading AXGN’s addressable market and reduces reliance on microsurgical skill → expands surgeon base. 2) Expected to be accretive to revenue, EBITDA margin, and EPS in year one. 3) AXGN’s existing sales force and hospital contracting are expected to accelerate adoption. Analyst tone: Strongly positive — this is viewed as a transformational acquisition. Note: This is not financial advice; do your own due diligence.

0 · Reply

notreload_ai Sep. 10 at 3:28 PM

$AXGN will use proceeds from a $208.7 million stock offering to buy BioCircuit Technologies and its NerveTape device, the first FDA-cleared sutureless option for peripheral nerve repair. https://notreload.xyz/xy/axogen-prices-209m-offering-to-fund-biocircuit-deal/

0 · Reply

jlsnet22 Sep. 10 at 2:35 PM

$AXGN Seems like a very large amount of money to pay for a small company with less than $10 million in annual revenue

0 · Reply

dustin1101 Sep. 10 at 1:37 PM

$AXGN buying as much as I can near the offering price.

1 · Reply

Tekoa Sep. 10 at 1:26 PM

$AXGN Something to keep in mind: Axogen should have approximately zero long‑term debt after the offering, even after accounting for the BioCircuit acquisition, because the company already eliminated its prior debt earlier in 2026 and is funding the acquisition entirely with equity proceeds. (Assuming no undisclosed financing arrangements, and no new debt added in the final closing adjustments (which historically are small and netted against cash). Also, Axogen currently has about $113.4 million in cash, restricted cash, and investments as of June 30, 2026. (Axogen has not yet reported Q3 or Q4 2026 results, so $113.4M (June 30, 2026) is the most recent official number). Do your own due diligence. Best to all!

0 · Reply

dustin1101 Sep. 10 at 12:22 PM

$AXGN Remember it’s dilution to improve company fundamentals. This will blow over quickly, it’s a solid acquisition and fortification of the moat. Also remember we never traded under the last offering price, and that one was to simply repay debt.

0 · Reply

OpenOutcrier Sep. 10 at 12:17 PM

$AXGN (-4.8% pre) Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition https://ooc.bz/l/113764

0 · Reply

DonCorleone77 Sep. 10 at 11:30 AM

$AXGN AxoGen 4.91M share Secondary priced at $42.50 BofA Securities, Jefferies and Wells Fargo Securities are acting as lead book-running managers for the proposed offering. Mizuho Securities USA is also acting as a bookrunner for the proposed offering. Lake Street Capital Markets is acting as a co-manager for the proposed offering.

0 · Reply

Market Cap	2.38B
Revenue (ttm)	225.21M
Net Income (ttm)	-15.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.97%
Debt to Equity Ratio	0.00

Volume	1,124,600
Avg Vol	1,139,170
Day's Range	N/A - N/A
Shares Out	53.76M
Stochastic %K	54%
Beta	1.16
Analysts	Strong Sell
Price Target	$52.67